Eli Lilly jumps after cancer drug trial
[at Financial Times] – Shares in Eli Lilly climbed after the US pharmaceuticals group said a study of a lung cancer treatment increased survival rates in patients, meeting the study’s primary goals. The drug, ramucirumab, is … moreView todays social media effects on CGView the latest stocks trending across Twitter. Click to view dashboardSee who The is hiring next, click […]